Skip to main content
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES — Investor Relations & Filings

Ticker · ABT ISIN · US0028241000 LEI · HQD377W2YR662HK5JX27 US Manufacturing
Open in API
Filings indexed 4,256 across all filing types
Latest filing 2016-06-03 Director's Dealing
Country US United States of America
Listing US ABT

About ABBOTT LABORATORIES

https://www.abbott.com

Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of life-changing technologies. The company's operations are focused on four core businesses: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The Medical Devices division offers solutions for cardiovascular health, diabetes care (including the FreeStyle Libre continuous glucose monitoring system), and neuromodulation. The Diagnostics segment provides a wide range of in vitro diagnostic systems and tests for hospitals, laboratories, and clinics. The Nutrition business develops and markets science-based nutritional products for people of all ages, with leading brands such as Similac, PediaSure, Ensure, and Glucerna. The Established Pharmaceuticals division provides a portfolio of branded generic medicines to consumers in emerging markets.

Recent filings

Filing Released Lang Actions
Statement of changes in Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a SEC Form 4 filing, which is a statement of changes in beneficial ownership of company securities by insiders such as officers or directors. It details transactions in the company's shares by a senior vice president and CFO, including dates, amounts, and prices. This type of filing is specifically used to report insider trades and is not a financial report, earnings release, or any other type of corporate report. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 4228 characters, which is typical for such filings and contains detailed transaction data, confirming it is not just an announcement or certification.
2016-06-03 English
Regulatory Filings 2016
Regulatory Filings
2016-06-01 English
SD
Regulatory Filings Classification · 95% confidence The document is a Form SD filed with the SEC, specifically a Specialized Disclosure Report related to conflict minerals for the year ended December 31, 2015. It references Rule 13p-1 under the Securities Exchange Act and includes a Conflict Minerals Report as an exhibit. The document length is 2920 characters, which is relatively short and primarily serves as a disclosure filing rather than a full financial or management report. Form SD filings are specialized disclosures required by the SEC for conflict minerals and do not fall under categories like Annual Report, Interim Report, or Earnings Release. Given the nature of the filing and its content, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2016-05-31 English
Abbott Laboratories Files Rule 425 Document
Call Transcript Classification · 100% confidence The document is a transcript of a conference call (specifically the Deutsche Bank Health Care Conference) featuring executives from Abbott Laboratories. It includes Q&A sessions and discussions regarding business strategy, M&A activity (St. Jude Medical), and financial outlook. This fits the definition of a Call Transcript (CT).
2016-05-09 English
425 Filing
Call Transcript Classification · 100% confidence The document is a transcript of a conference call held by Abbott Laboratories at the Deutsche Bank Health Care Conference on May 5, 2016. It includes detailed discussions by senior executives about strategic direction, acquisition rationale, due diligence, market positioning, and growth prospects related to the St. Jude Medical transaction. The content is a verbatim record of the Q&A and presentations during the call, which is typical of earnings or investor conference call transcripts. There is no indication that this is a formal earnings release (which would be shorter and more summary-like), nor is it a full annual or interim report. It is not an announcement of a report, nor a regulatory filing or certification. The presence of multiple participants, forward-looking statements disclaimers, and detailed Q&A confirms this is a Call Transcript (CT).
2016-05-06 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2016, reporting on the submission of matters to a vote of security holders at Abbott Laboratories' Annual Meeting of Shareholders. It details the voting results for the election of the Board of Directors, ratification of auditors, and approval of executive compensation. The content focuses exclusively on the official results of shareholder votes at the meeting. The document length is 4258 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-05-04 English

Browse filings by year

33 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.